Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.35 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13617069 | 0.92 | ADRB3 (0.48) | ELANEKCNH2CYP3A4CTSBADRB3 | |
| SCHEMBL13617067 | 0.89 | ADRB3 (0.43) | ELANEKCNH2CYP3A4CTSBADRB3 | |
| SCHEMBL8001496 | 0.88 | CTSB (0.47) | ELANEKCNH2CYP3A4CTSBADRB3 | |
| SCHEMBL12792589 | 0.84 | CYP3A4 (0.51) | ELANEKCNH2CYP3A4CTSBADRB3 | |
| SCHEMBL13617100 | 0.83 | ADRB3 (0.45) | ELANEKCNH2CYP3A4CTSBADRB3 | |
| SCHEMBL14913795 | 0.82 | CYP3A4 (0.52) | ELANEKCNH2CYP3A4CTSBADRB3 | |
| SCHEMBL14913646 | 0.82 | CYP3A4 (0.52) | ELANEKCNH2CYP3A4CTSBADRB3 | |
| SCHEMBL14913642 | 0.82 | CYP3A4 (0.52) | ELANEKCNH2CYP3A4CTSBADRB3 | |
| SCHEMBL14913794 | 0.82 | CYP3A4 (0.52) | ELANEKCNH2CYP3A4CTSBADRB3 | |
| SCHEMBL18142841 | 0.80 | CYP3A4 (0.59) | ELANEKCNH2CYP3A4CTSBADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285773-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-19 | — | — | US | disclosed |
| US-20090285773-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285773-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | ELANE 1285/4885KCNH2 3734/4885CYP3A4 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.